This article originally appeared as part of The Vendor Edge series on LinkedIn. This is an expanded and updated version for kieranengels.com.
Risk is not something to eliminate. It’s a diagnostic tool. Most clinical development teams respond to risk by building more controls, adding more oversight, and pushing the problem downstream. The teams that actually move fast are the ones who read risk signals early, understand what they mean about governance and vendor readiness, and use that information to make better decisions upstream. When risk is treated as information rather than threat, it becomes one of the most powerful steering tools in a sponsor’s toolkit.
KEY TAKEAWAYS
Key Takeaways
- Risk signals reveal gaps in governance, vendor alignment, and execution readiness, not inherent project danger.
- Sponsors who treat risk as information make better decisions earlier and move faster downstream.
- Governance-informed risk reading prevents the cascade of rework, scope creep, and timeline pressure that derails timelines.
- Vendor risk is not about capability gaps. It’s about misalignment between what you need and what they can deliver.
- Reading risk means asking: What does this tell us? What was unclear upstream? What needs to change now?
Let’s be clear about what risk actually is. Risk in clinical development isn’t inherent danger. It’s information. It tells you something about the clarity of your governance, the readiness of your vendors, and the alignment between what you’re asking people to do and what they understand they’re supposed to deliver.
Understanding the Fundamentals
The problem is how sponsors respond to that information. Most clinical development leaders see a risk signal and treat it like a threat. They build another control. They add another approval gate. They escalate the decision. The risk doesn’t go away. It just gets buried deeper, waits longer, and explodes bigger downstream.
Kieran Engels and the team at Seuss+ have spent the last decade watching this pattern repeat. Teams that move fast in clinical development aren’t the ones with the most controls. They’re the ones with the clearest upstream governance. They read risk early, diagnose what it means, and use that diagnosis to reframe the problem.
The Real Cost of Misalignment
Here’s the cognitive shift: Risk is not a problem to solve. It’s a signal to read. When a vendor proposal contradicts itself, that’s not a vendor problem. That’s a governance problem. It means your requirements weren’t clear enough for them to hit. When a timeline is beginning to slip, that’s not a capacity problem. That’s an alignment problem. It means someone isn’t clear on priorities.
The teams that actually succeed understand the difference. They use risk as a diagnostic tool. They ask: What does this signal tell us about clarity, alignment, and readiness? What was supposed to happen that didn’t? What’s the upstream cause?
Building Governance Infrastructure
This isn’t about lower risk. This is about faster decision-making. When you can read risk signals and translate them into specific governance changes, you solve problems before they become crises. You prevent the months of rework that come from discovering misalignment after execution has already begun.
Governance-informed risk reading also changes how you evaluate vendors. Vendor risk is not about whether they’re capable. It’s about whether there’s alignment between what you need and what they actually deliver. A vendor might be technically excellent but structurally misaligned with your decision-making cadence. That’s a risk signal. It tells you something needs to change in how you’re partnering with them.
The Speed Advantage
The truth is that Kieran Engels has watched sponsors spend millions on additional vendor oversight because they couldn’t read the upstream risk signals. The additional controls don’t fix the problem. They slow everything down. What fixes it is going back to the beginning and asking: What was supposed to be clear that wasn’t? What alignment is missing?
This is why governance isn’t overhead. Governance is the system that lets you read risk signals early and respond before they cascade. Every hour you spend getting clear on roles, decision rights, and expectations upstream is an hour that prevents three hours of rework, escalation, and crisis management downstream.
Risk-informed governance also changes how you manage speed. Speed without visibility is panic. Speed with clear governance and honest risk reading is acceleration. The difference is whether you can see the problems coming.
Risk Signals vs. Typical Response vs. Governance-Informed Response
| Risk Signal | Typical Sponsor Response | Governance-Informed Response |
| Vendor proposal contradicts itself on timeline or staffing | Request clarification; assume miscommunication | Diagnose: requirements weren’t clear enough. Clarify upstream decision-making and staffing model upfront. |
| Timeline pressure increases as execution begins | Add more oversight; escalate status reviews | Diagnose: misalignment on priorities or scope. Reset decision rights and approval cadence. |
| Vendor reports scope ambiguity mid-project | Expand contract language; add change management layers | Diagnose: governance wasn’t clear at kickoff. Define decision rights and scope boundaries before execution. |
| Staffing turnover or key resource unavailability | Request replacement; demand bench strengthening | Diagnose: vendor model doesn’t align with your needs. Renegotiate staffing clarity and continuity expectations. |
| Multiple stakeholders disagree on vendor performance | Commission audit; demand more reporting | Diagnose: KPIs weren’t defined or agreed. Establish shared performance definition and feedback rhythm. |
Risk isn't a problem to solve. It's a signal to read. The teams that move fastest in clinical development are the ones who can diagnose what risk tells them about governance, alignment, and readiness, and act on that diagnosis before the problem cascades.
Key Industry Data
An estimated $20 billion in annual R&D spending is wasted due to poor clinical trial management and preventable failures. (Source: Clinical Trials Transformation Initiative)
A single protocol amendment in a Phase III trial adds approximately three months and over $500,000 in unbudgeted direct costs. (Source: Tufts CSDD)
Nearly 60% of all trial protocols require at least one amendment, with one third of those amendments being avoidable. (Source: Tufts CSDD)
39% of Phase III small molecule trials fail to progress to a regulatory application. (Source: Tufts CSDD)
Only 11.8% of drugs entering clinical testing ultimately gain regulatory approval. (Source: Tufts CSDD)
Frequently Asked Questions
The test is whether additional oversight actually solves the problem. If you add another approval gate and the same issue reappears, it’s a governance problem, not a control problem. True governance changes are about clarity upstream, not visibility downstream. Ask: What decision wasn’t made clearly? What alignment is missing? What role needs to be redefined?
Vendor risk is what you see: capacity shortfalls, capability gaps, or execution failures. Governance risk is what caused it: unclear requirements, misaligned expectations, or weak decision-making. You can’t fix vendor risk by auditing the vendor more. You fix it by diagnosing and clearing up the governance problem upstream.
The opposite. When you can accurately diagnose what a risk signal means, you can make faster decisions because you’re solving the real problem, not the symptom. Sponsors who ignore risk signals and just push harder end up reworking months later. Reading risk means solving it once.
Start by making diagnosis a required step before response. When a risk is raised, ask: What does this tell us about governance, clarity, or alignment? What upstream decision or definition was supposed to prevent this? Require teams to propose the governance change they’d make, not just the control they’d add.
It shifts focus from polish and reputation to operational evidence. You’re asking: Can this vendor articulate how they handle constraints? What does their staffing model actually look like? Do they align with how you make decisions? Risk signals from their proposal tell you whether they’re aligned with your governance model, not whether they’re technically capable.
About the Author
Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.
